Statin induced myopathy and myalgia: Time trend analysis and comparison of risk associated with statin class from 1991-2006

PLoS ONE

Volumn 3, Issue 6, 2008, Pages

  Molokhia, Mariam ^a   McKeigue, Paul ^b   Curcin, Vasa ^c   Majeed, Azeem ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; FACTUAL DATABASE; FASCIA DISEASE; FEMALE; FIBROMYALGIA; HUMAN; INCIDENCE; LIGAMENT DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULAR DYSTROPHY; MYALGIA; MYOFIBROSIS; MYOPATHY; MYOSITIS; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RHEUMATIC DISEASE; RISK ASSESSMENT; SIDE EFFECT; TIME; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG SURVEILLANCE PROGRAM; MIDDLE AGED; MUSCLE DISEASE; UNITED KINGDOM; UNITED STATES;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CROSS-OVER STUDIES; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES;

EID: 49649119693     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002522     Document Type: Article

References (27)

1. Stricker BH, Psaty BM (2004) Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47.
2. National Audit Office study team (2007) Prescribing costs in primary care. pp 1-39.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
4. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329: 15-19.
5. Armitage J (2007) The safety of statins in clinical practice. Lancet.
6. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE (2007) Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol 60: 812-818.
7. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH (2001) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12: 565-569.
8. Majeed A (2004) Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 5-14.
9. Maclure M (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133: 144-153.
10. Farrington P, Pugh S, Colville A, Flower A, Nash J, et al. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/ pertussis and measles/mumps/rubella vaccines. Lancet 345: 567-569.
11. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H (1998) Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 351: 1467-1471.
12. Garcia Rodriguez LA, Perez GS (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419-425.
13. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH (1999) A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48: 847-852.
14. Meier CR, Wilcock K, Jick SS (2004) The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 27: 203-213.
15. van der Linden PD, van der LJ, Vlug AE, Stricker BH (1998) Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 51: 703-708.
16. Wood L, Martinez C (2004) The general practice research database: role in pharmacovigilance. Drug Saf 27: 871-881.
17. Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD (2005) Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol 3: 459-465.
18. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, et al. (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113: 2906-2913.
19. Hebert C, Delaney JA, Hemmelgarn B, Levesque LE, Suissa S (2007) Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs. Pharmacoepidemiol Drug Saf 16: 845-849.
20. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
21. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT (2006) Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 98: 51-54.
22. [Anonymous] (2007) InforSense KDE factsheet: http://www.inforsense.com/ pdfs/InforSense_KDE_Factsheet.pdf.
23. Rowe A, Kalaitzopoulos D, Osmond M, Ghanem M, Guo Y (2003) The discovery net system for high throughput bioinformatics. ISMB (Supplement of Bioinformatics) 225-231.
24. Department of Health (DoH, 2001) (2001) National Service Framework for Diabetes: Standards.
25. National Institute for Health and Clinical Excellence (NICE) (2006) Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease.
26. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590.
27. Black C, Jick H (2002) Etiology and frequency of rhabdomyolysis. Pharmacotherapy 22: 1524-1526.